Breckenridge recalls one lot of blood pressure drug over metal contamination risk
A single lot of generic propranolol extended-release capsules shipped nationwide in late October may contain metal fragments capable of cutting the mouth or digestive tract, the manufacturer says, the latest in a string of 2026 quality problems tied to generic heart and blood-pressure drugs.
Breckenridge Pharmaceutical Inc. said this week that it is voluntarily recalling one lot of a widely used blood-pressure and heart-rhythm drug after discovering that capsules from the batch may contain small metal fragments. The company's recall notice, distributed nationwide through PR Newswire on Nov. 16, warns that the fragments could cut the mouth, throat, stomach or intestines if swallowed.
The recalled product is Propranolol Hydrochloride Extended-Release Capsules, USP, 60 milligrams, a generic version of a decades-old beta-blocker prescribed for high blood pressure, irregular heart rhythms, migraine prevention and tremor. Breckenridge, a New Jersey-based generic drugmaker, said it has not received any reports of injury connected to the recalled lot.
What the recall covers
The affected capsules were sold in 100-count bottles under National Drug Code 51991-817-01, lot number PK25110035, with an expiration date of May 2029. Breckenridge shipped the lot to wholesalers and pharmacies across the country over roughly a week and a half, between Oct. 26 and Nov. 4, according to the company's notice. The firm has not disclosed how many bottles were distributed.
The capsules were manufactured for Breckenridge by Adare Pharma Solutions, a contract drugmaker that produces propranolol using a specialized time-release coating technology. In its recall notice, the company said the affected lot "shared intermediate material suspected to be the source of metal contamination" that had already been found in a separate lot of the drug — one that was caught before it reached the market. That detail suggests the contamination was identified upstream, in a shared manufacturing input, rather than in a single mishandled batch.
"Use of product from the affected lot could potentially cause lacerations of soft tissues in the oral cavity, esophagus, stomach or intestine," Breckenridge said in its recall notice.
A recurring strain on generic heart and blood-pressure drugs
The propranolol recall is the latest in a string of manufacturing problems to hit generic cardiovascular medications in 2026. Earlier this year, FDA-tracked recall notices covered more than 11,000 bottles of chlorthalidone, a diuretic used to treat hypertension, after tablets made by Inventia Healthcare and distributed by Rising Pharma failed dissolution testing — meaning the pills might not break down and release their active ingredient properly in the body. A second chlorthalidone recall followed in the fall, and a combination amlodipine-and-olmesartan blood-pressure tablet made in India for Ascend Laboratories was pulled for the same dissolution problem in the spring.
Those episodes, along with this week's metal-contamination finding, point to recurring quality-control lapses across the generic drug supply chain that keeps tens of millions of Americans on daily blood-pressure regimens. Generic manufacturers supply the vast majority of cardiovascular prescriptions filled in the United States, and recalls tied to manufacturing defects — as opposed to the drug's chemistry itself — have become more frequent in recent years as production has concentrated among a smaller number of contract manufacturers here and abroad.
Who is affected
The population with a direct stake in the recall is narrow: only patients who filled a 60-milligram propranolol extended-release prescription from the specific lot, at a pharmacy that received stock during the late-October shipping window, are affected. But the drug's reach is broad. Propranolol is prescribed not only for hypertension but also for performance anxiety, essential tremor and migraine prevention, meaning the recalled lot could have reached patients well beyond those managing blood pressure. Nationally, the scale of blood-pressure treatment underscores why even a single-lot recall draws attention: the Centers for Disease Control and Prevention estimates that 48.1 percent of American adults — nearly 120 million people — have high blood pressure, and only about 22.5 percent of them have it under control.
- Patients with bottles matching NDC 51991-817-01 and lot PK25110035 should stop taking the capsules and contact their prescriber for replacement instructions rather than simply discontinuing the medication on their own.
- Unused capsules should be returned to the pharmacy where they were purchased.
- Pharmacies and wholesalers are instructed to quarantine remaining stock from the lot and stop dispensing or distributing it.
- Anyone who experiences a problem that might be related to the capsules is asked to report it through the FDA's MedWatch adverse-event reporting program.
Clinicians generally caution against stopping a beta-blocker abruptly without medical guidance, since doing so can, in some patients, trigger a rebound rise in heart rate or blood pressure. That is consistent with Breckenridge's own instruction, which directs patients to their physician for "replacement instructions" rather than simply telling them to go without the medication.
Company response and what happens next
Breckenridge said the recall is being carried out with the knowledge of the Food and Drug Administration, and it has retained Qualanex, a third-party recall management firm, to field questions from patients and pharmacies at a dedicated phone line and email address. NBC Chicago reported that the company did not immediately respond to a request for further comment, and Fox Business likewise noted that no injuries had been confirmed as of its report Nov. 17.
The FDA had not yet posted its own formal risk classification of the recall as of this week, a step that typically follows a company's initial notice by several days and determines how urgently the agency treats the hazard. In the meantime, pharmacists are checking incoming and shelved stock against the lot number, a routine but labor-intensive process that follows nearly every drug recall. Patients who are unsure whether their bottle came from the affected lot are advised to check the label against the NDC and lot number directly or ask their pharmacist, rather than guessing based on when or where a prescription was filled.
Herbal Supplement Maker Recalls Yellow Dock Root Over Salmonella Risk

Fewer Hospitals Fail Safety Grades, But Court Fight Leaves 450 Unrated

Gelato maker recalls chocolate banana dessert bars after pistachio mix-up
